Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Brunner

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Stroke|June 4, 2005
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery diseaseSophie Ziegler, Martin Schillinger, Marion Funk, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 5, 2005
Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humansOliver Langer, Rudolf Karch, Ulrich Müller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 4, 2005
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PETOliver Langer, Martin Brunner, Markus Zeitlinger, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humansMartin Brunner, Oliver Langer, Raute Sunder-Plassmann, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Epilepsia|May 9, 2007
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamilOliver Langer, Martin Bauer, Alexander Hammers, et al.
JMIR Medical Informatics|June 17, 2022
Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert ConsensusPeter Klimek, Dejan Baltic, Martin Brunner, et al.
Alzheimer'S Research & Therapy|October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's diseasePetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Clinical Pharmacology and Therapeutics|September 6, 2006
A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's diseaseMartin Bauer, Oliver Langer, Peter Dal-Bianco, et al.
The Lancet. Neurology|December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trialPetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Stroke|June 4, 2005
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery diseaseSophie Ziegler, Martin Schillinger, Marion Funk, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 5, 2005
Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humansOliver Langer, Rudolf Karch, Ulrich Müller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 4, 2005
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PETOliver Langer, Martin Brunner, Markus Zeitlinger, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humansMartin Brunner, Oliver Langer, Raute Sunder-Plassmann, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Epilepsia|May 9, 2007
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamilOliver Langer, Martin Bauer, Alexander Hammers, et al.
JMIR Medical Informatics|June 17, 2022
Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert ConsensusPeter Klimek, Dejan Baltic, Martin Brunner, et al.
Alzheimer'S Research & Therapy|October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's diseasePetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Clinical Pharmacology and Therapeutics|September 6, 2006
A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's diseaseMartin Bauer, Oliver Langer, Peter Dal-Bianco, et al.
The Lancet. Neurology|December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trialPetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Pageof 7